| Date | Title | Description |
| 29.10.2024 | Aignostics Secures $34M to Advance AI-Powered Pathology and Precision Medicine | What You Should Know:
– Aignostics, a leading AI company specializing in pathology data analysis, raised $34M in Series B funding, led by ATHOS with participation from Mayo Clinic and growth financing from HTGF, alongisde existing investors... |
| 30.07.2024 | Synthetica Pioneering Closes a Series A Funding Round to Support Development of Oncolytic Bacterial Therapy for Solid Tumors | SHENZHEN, China, July 30, 2024 /PRNewswire/ -- Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup specializing in synthetic biology for engineering novel living bacterial therapeutics, has recently closed a Series A fu... |
| 30.07.2024 | Synthetica Pioneering Closes a Series A Funding Round to Support Development of Oncolytic Bacterial Therapy for Solid Tumors | SHENZHEN, China, July 30, 2024 /PRNewswire/ -- Shenzhen Synthetica Pioneering Co., Ltd. (Synthetica), a biotech startup specializing in synthetic biology for engineering novel living bacterial therapeutics, has recently closed a Series A fu... |
| 14.11.2023 | Scotland’s Glox Therapeutics raises €4.9M to combat antimicrobial resistance | Read this article in:
Glasgow-based Glox Therapeutics, a company that aims to advance its precision antibiotic therapies, focusing on naturally occurring bacteriocins, has secured £4.3M (approximately €4.93M) in a seed round of funding.
The... |
| 23.05.2023 | m4 Award winner smartbax completes seed funding of EUR 1.2 million to develop innovative antibiotics against multi-resistant bacteria | Munich-based biotech company and m4 Award winner smartbax, which develops next-generation antibiotics, has closed a EUR 1.2 million seed financing round with Boehringer Ingelheim Venture Fund (BIVF) and High-Tech Gründerfonds (HTGF). With t... |
| 11.05.2023 | Biotech startup DiogenX secures €27.5M to develop therapeutic solutions for Type 1 diabetes | Marseille-based DiogenX, a preclinical-stage biotech company specialising in the development of pancreatic beta-cell modulators for the treatment of diabetes, announced on Wednesday, May 10, that it has raised €27.5M in a Series A round of ... |
| 15.09.2022 | Berlin-based Aignostics scoops €14 million to decode diagnostics with AI-driven pathology platform | While pathologists are outstanding at interpreting individual tissue samples qualitatively, deep analysis of large data sets is a challenge better suited for AI. Attempting to address this, Berlin-based biotech startup Aignostics focuses on... |
| 18.06.2021 | Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies | SINGAPORE, June 18, 2021 /PRNewswire/ -- Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round. The round was ... |
| 22.07.2020 | T3 Pharma raises CHF 25M to advance bacterial cancer therapy | Founded in 2015 as a spin-off from the Biozentrum of the University of Basel, T3 Pharma built a proprietary protein delivery platform by repurposing the bacterial type III secretion (T3S) system. ts lead product, T3P-Y058-739 T3P-Y058-739 i... |
| 22.07.2020 | T3 Pharma raises CHF 25M to advance bacterial cancer therapy | |
| 10.01.2020 | NBE-Therapeutics closes USD 22 million financing round | |
| 10.01.2020 | NBE-Therapeutics closes USD 22 million financing round | NBE-Therapeutics’ best in class iADC platform creates highly potent and safe immune-stimulatory ADCs (Antibody Drug Conjugates) - Antibodies attached to biologically active drugs by chemical linkers. NBE’s ADCs include an anthracycline payl... |
| 26.09.2019 | Financing Round Paves the Way for T3 Pharma to Enter the Clinic | |
| 12.11.2018 | AMAL Therapeutics finalises CHF 33 million Series B round | |
| 05.09.2017 | AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round | Financing round co-led by Boehringer Ingelheim Venture Fund, BioMedPartners and Helsinn Investment Fund |
| 03.11.2016 | NBE Therapeutics Raises CHF 20 Million in Series B Funding | |
| 11.04.2016 | Daily funding roundup - April 11, 2016 | Ticket Monster raised $40M; STAT-Diagnostica closed Series C; Marxent received $10M investment
Habito, a London-based online mortgage broker, raised £1.5 million (approximately $2.13 million) in seed funding in a round led by Mosaic Venture... |
| 30.03.2016 | Daily funding roundup - March 30, 2016 | Zavante closed $45M Series A funding; MapD secured $10M; Invoca closed $30M Series D funding
Invoca, a marketing platform for call analytics and automation, closed a $30 million Series D round of funding led by Morgan Stanley Alternative In... |
| 30.03.2016 | Amal Therapeutics raises CHF 3 million in a Series A financing round | |
| 14.10.2014 | Rigontec Raises €9.45M in Series A Financing | Rigontec GmbH, a Bonn, Germany-based biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, raised €9.45m in Series A financing.
The round was co-led by Wellington Partners and Boeh... |
| 25.03.2014 | Amal Therapeutics, un exemple de recherche de Seed financing dans le domaine biotech | |
| 24.03.2014 | Emerging sources of early-stage life science funding embrace the role of ‘venture catalysts’ | “The biggest challenge for the pharmaceutical company is actually coming up with a product that works,” said Jeffrey Moore, managing partner of Healthcare Venture Management. So other factors like a startup’s executive team become less impo... |
| 21.02.2014 | Amal Therapeutics Raises Seed Funding | Amal Therapeutics SA, a Geneva, Switzerland and Berlin, Germany-based company focusing on the development of therapeutic cancer vaccines, raised a seed round of funding.
The round – whose amount was not disclosed – was led by Boehringer Ing... |
| 20.02.2014 | Amal Therapeutics SA raises seed round from Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds | |
| 29.05.2013 | GSK acquires Okairos AG for EUR 250 mio | |
| 06.05.2013 | STAT-Diagnóstica cierra una ronda de €17M e incorpora inversores internacionales de referencia | 06/05/2013
Nota de Prensa
STAT-DIAGNOSTICA CIERRA UNA RONDA DE €17 MILLONES E INCORPORA INVERSORES INTERNACIONALES DE REFERENCIA.
STAT-Diagnostica, compañía especializada en el desarrollo de sistemas de diagnóstico Point of Care (próximo... |
| 06.05.2013 | STAT-Diagnostica Closes €17M Series B Financing | STAT-Diagnostica, a Barcelona, Spain-based provider of a Near Patient Testing diagnostic system, closed a €17m (approxiamtely $22.1m) Series B financing round.
The round was led by new investor Kurma Life Sciences Partners, with participati... |
| 11.04.2013 | Eyevensys Raises Funds from Boehringer Ingelheim Venture Fund | Eyevensys, a Paris, France-developer of a new non-viral gene therapy process to treat ocular illnesses, announces an equity investment of undisclosed amount by Boehringer Ingelheim Venture Fund.
In conjunction with the funding, Dr Michel Pa... |
| 03.12.2012 | ArmaGen Technologies Raises $17M in Series A Funding | ArmaGen Technologies, a Santa Monica, CA-based developer of brain-penetrating recombinant protein therapeutics, has raised $17m in Series A funding.
The round was led by Boehringer Ingelheim Venture Fund, with participation from Shire plc, ... |
| 31.03.2010 | Ben Venue, Roxane parent launches $135M life sciences fund | These are new areas of investment for Boehringer Ingelheim, which in Ohio is known for making generic drugs through its Ben Venue Laboratories and Roxane Laboratories units in Bedford Heights and Columbus, respectively. Last year, the Germa... |
| - | Emerging sources of early-stage life science funding embrace the role of ‘venture catalysts’ | It was nice to hear one healthcare executive and investor after another respond to the question, “what are your key priorities when evaluating a deal?” with the answer, “really compelling science.”
I’ve often heard VCs and angel investors c... |
| - | AMAL Therapeutics finalises €29 million (CHF 33.2 million) Series B round | |
| - | Aignostics raises €5m Seed Round to advance AI-powered pathology | Aignostics, a spin-off from Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, pioneering computational pathology for pharmaceutical research and diagnostics, has announced today the closing of €5m in seed round fundin... |
| - | Abalos Therapeutics Launches with €12M Series A Round to Develop Novel Immuno-Virotherapies Against Cancer | Abalos Therapeutics announced today a EUR 12 million Series A financing round establishing its operations and leadership. The Company’s objective is to develop new immuno-oncology therapeutics based on a specific arenavirus strain that pref... |
| - | Bayer and Boehringer Ingelheim invest in HTGF III | Bayer and Boehringer Ingelheim’s investment fund BIVF (Boehringer Ingelheim Venture Fund) are investing in High-Tech Gründerfonds’ third fund, HTGF III. The investment grants the two international pharmaceutical companies access to innovati... |
| - | Tacalyx Raises €7 Million in Seed Funding to Generate First in Class Anti-TACA Antibodies for Cancer Treatment | Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA (Tumor Associated Carbohydrate Antigens) cancer therapies, today announced that it has successfully secured €7 million in seed funding. The funding round... |
| - | Abalos Therapeutics Completes Series A Extension Bringing Total Raised to EUR 43 Million | October 14, 2021 |
| - | Ben Venue, Roxane parent launches $135M life sciences fund | The German parent of Ben Venue and Roxane drug-making facilities in Ohio has launched a $135 million venture fund to foster innovation in the life sciences.
Boehringer Ingelheim GmbH of Ingelheim, Germany, started Boehringer Ingelheim Ventu... |
| - | Amal Therapeutics raises CHF 3 million in a Series A financing round led by Boehringer Ingelheim Venture Fund | Amal Therapeutics (Amal) completes CHF 3 million (EUR 2.75 million) Series A financing round with Boehringer Ingelheim Venture Fund (BIVF) as cornerstone investors. VI Partners and High-Tech Gründerfonds also participated in the round which... |
